333 related articles for article (PubMed ID: 28178182)
1. Effects of Magnesium on the Phosphate Toxicity in Chronic Kidney Disease: Time for Intervention Studies.
Sakaguchi Y; Hamano T; Isaka Y
Nutrients; 2017 Feb; 9(2):. PubMed ID: 28178182
[TBL] [Abstract][Full Text] [Related]
2. Magnesium and Progression of Chronic Kidney Disease: Benefits Beyond Cardiovascular Protection?
Sakaguchi Y; Hamano T; Isaka Y
Adv Chronic Kidney Dis; 2018 May; 25(3):274-280. PubMed ID: 29793667
[TBL] [Abstract][Full Text] [Related]
3. Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification.
Tatsumoto N; Yamada S; Tokumoto M; Eriguchi M; Noguchi H; Torisu K; Tsuruya K; Kitazono T
Am J Physiol Renal Physiol; 2015 Dec; 309(11):F967-79. PubMed ID: 26336165
[TBL] [Abstract][Full Text] [Related]
4. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
5. Relationship between magnesium and clinical biomarkers on inhibition of vascular calcification.
Salem S; Bruck H; Bahlmann FH; Peter M; Passlick-Deetjen J; Kretschmer A; Steppan S; Volsek M; Kribben A; Nierhaus M; Jankowski V; Zidek W; Jankowski J
Am J Nephrol; 2012; 35(1):31-9. PubMed ID: 22179063
[TBL] [Abstract][Full Text] [Related]
6. Optimal use of phosphate binders in chronic kidney disease.
Sonikian M; Papachristou E; Goumenos DS
Expert Opin Pharmacother; 2013 Dec; 14(18):2521-32. PubMed ID: 24215605
[TBL] [Abstract][Full Text] [Related]
7. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study.
Sakaguchi Y; Fujii N; Shoji T; Hayashi T; Rakugi H; Iseki K; Tsubakihara Y; Isaka Y;
PLoS One; 2014; 9(12):e116273. PubMed ID: 25545498
[TBL] [Abstract][Full Text] [Related]
8. Advances in pharmacotherapy for hyperphosphatemia in renal disease.
Spasovski G
Expert Opin Pharmacother; 2015; 16(17):2589-99. PubMed ID: 26374200
[TBL] [Abstract][Full Text] [Related]
9. Magnesium modifies the association between serum phosphate and the risk of progression to end-stage kidney disease in patients with non-diabetic chronic kidney disease.
Sakaguchi Y; Iwatani H; Hamano T; Tomida K; Kawabata H; Kusunoki Y; Shimomura A; Matsui I; Hayashi T; Tsubakihara Y; Isaka Y; Rakugi H
Kidney Int; 2015 Oct; 88(4):833-42. PubMed ID: 26061542
[TBL] [Abstract][Full Text] [Related]
10. Phosphate in early chronic kidney disease: associations with clinical outcomes and a target to reduce cardiovascular risk.
Toussaint ND; Pedagogos E; Tan SJ; Badve SV; Hawley CM; Perkovic V; Elder GJ
Nephrology (Carlton); 2012 Jul; 17(5):433-44. PubMed ID: 22574672
[TBL] [Abstract][Full Text] [Related]
11. Magnesium to prevent kidney disease-associated vascular calcification: crystal clear?
Ter Braake AD; Vervloet MG; de Baaij JHF; Hoenderop JGJ
Nephrol Dial Transplant; 2022 Feb; 37(3):421-429. PubMed ID: 33374019
[TBL] [Abstract][Full Text] [Related]
12. The effect of magnesium supplementation on vascular calcification in chronic kidney disease-a randomised clinical trial (MAGiCAL-CKD): essential study design and rationale.
Bressendorff I; Hansen D; Schou M; Kragelund C; Brandi L
BMJ Open; 2017 Jun; 7(6):e016795. PubMed ID: 28645983
[TBL] [Abstract][Full Text] [Related]
13. Dietary magnesium supplementation inhibits abdominal vascular calcification in an experimental animal model of chronic kidney disease.
Leenders NHJ; Bos C; Hoekstra T; Schurgers LJ; Vervloet MG; Hoenderop JGJ
Nephrol Dial Transplant; 2022 May; 37(6):1049-1058. PubMed ID: 35134986
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of magnesium in CKD.
Sakaguchi Y
Clin Exp Nephrol; 2022 May; 26(5):379-384. PubMed ID: 35076791
[TBL] [Abstract][Full Text] [Related]
15. Reversal Of Arterial Disease by modulating Magnesium and Phosphate (ROADMAP-study): rationale and design of a randomized controlled trial assessing the effects of magnesium citrate supplementation and phosphate-binding therapy on arterial stiffness in moderate chronic kidney disease.
Vermeulen EA; Eelderink C; Hoekstra T; van Ballegooijen AJ; Raijmakers P; Beulens JW; de Borst MH; Vervloet MG
Trials; 2022 Sep; 23(1):769. PubMed ID: 36096824
[TBL] [Abstract][Full Text] [Related]
16. Preventive Strategies for Vascular Calcification in Patients with Chronic Kidney Disease.
Shigematsu T; Sonou T; Ohya M; Yokoyama K; Yoshida H; Yokoo T; Okuda K; Masumoto AR; Iwashita Y; Iseki K; Kunimoto S; Yamano Y
Contrib Nephrol; 2017; 189():169-177. PubMed ID: 27951564
[TBL] [Abstract][Full Text] [Related]
17. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials.
Patel L; Bernard LM; Elder GJ
Clin J Am Soc Nephrol; 2016 Feb; 11(2):232-44. PubMed ID: 26668024
[TBL] [Abstract][Full Text] [Related]
18. Vascular toxicity of phosphate in chronic kidney disease: beyond vascular calcification .
Gross P; Six I; Kamel S; Massy ZA
Circ J; 2014; 78(10):2339-46. PubMed ID: 25077548
[TBL] [Abstract][Full Text] [Related]
19. Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: a comparison of safety profiles.
Locatelli F; Del Vecchio L; Violo L; Pontoriero G
Expert Opin Drug Saf; 2014 May; 13(5):551-61. PubMed ID: 24702470
[TBL] [Abstract][Full Text] [Related]
20. Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.
Kanbay M; Yilmaz MI; Apetrii M; Saglam M; Yaman H; Unal HU; Gok M; Caglar K; Oguz Y; Yenicesu M; Cetinkaya H; Eyileten T; Acikel C; Vural A; Covic A
Am J Nephrol; 2012; 36(3):228-37. PubMed ID: 22948239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
